BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil.

The American Academy of Orthopaedic Surgeons presented its 2021 William W. Tipton Jr., MD, Leadership Award to Joseph D. Zuckerman, MD, FAAOS.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Orphan Drug Designation (ODD) to gavo-cel for the treatment of cholangiocarcinoma.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the launch of Duet Therapeutics.

Saint-Gobain Life Sciences announced today the acquisition of Equflow B.V., located in Oss, Netherlands.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference.

Rise in animal health awareness. Furthermore, increase in prevalence of animal disease, along with growing number of pet adoption are expected to boost the requirement of veterinary imaging in the coming years.

Waters Corporation Udit Batra Ph.D., President and Chief Executive Officer, will present at the Bank of America Global Healthcare Conference 2021 virtually on Thursday, September 16th, 2021 at 3:55PM BST / 10:55AM Eastern Time.

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), and BioXcel Therapeutics, Inc. (“BioXcel”), announce the publication of BioXcel’s International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will participate in the Morgan Stanley 19th Annual Global Healthcare Conference.